The estimated Net Worth of Bo Kruse is at least $9.39 Миллион dollars as of 30 May 2024. Mr. Kruse owns over 60,000 units of Y-Mabs Therapeutics Inc stock worth over $3,214,631 and over the last 6 years he sold YMAB stock worth over $5,564,680. In addition, he makes $608,347 as Chief Financial Officer, Executive Vice President, Treasurer, Secretary и Director at Y-Mabs Therapeutics Inc.
Sign up
Mr. Kruse YMAB stock SEC Form 4 insiders trading
Bo has made over 21 trades of the Y-Mabs Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of YMAB stock worth $120,000 on 30 May 2024.
The largest trade he's ever made was selling 100,000 units of Y-Mabs Therapeutics Inc stock on 13 May 2020 worth over $3,665,000. On average, Bo trades about 8,429 units every 53 days since 2018. As of 30 May 2024 he still owns at least 242,248 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mr. Kruse stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bo Kruse biography
Bo Kruse serves as Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director of the Company. Mr. Kruse has served as our Executive Vice President, Secretary, Treasurer and Chief Financial Officer since June 2015. Mr. Kruse has also served as a member of our Board of Directors since June 2015. Mr. Kruse has broad international finance experience, including knowledge of capital markets, accounting and other financing activities. Prior to joining our company, Mr. Kruse was Azanta's Chief Financial Officer from 2009 to 2015. Further, Mr. Kruse served as Genmab's Vice President and Chief Financial Officer from 2005 to 2008 and in a number of other positions, including as Vice President and Chief Accounting Officer from 2000 to 2005. During his tenure at Genmab, Mr. Kruse was directly involved in several financing rounds, including Genmab's initial public offering in 2000. Mr. Kruse has a M.Sc. in Business Economics and Auditing from the Copenhagen Business School.
What is the salary of Bo Kruse?
As the Chief Financial Officer, Executive Vice President, Treasurer, Secretary и Director of Y-Mabs Therapeutics Inc, the total compensation of Bo Kruse at Y-Mabs Therapeutics Inc is $608,347. There are 4 executives at Y-Mabs Therapeutics Inc getting paid more, with Claus Moller-San Pedro having the highest compensation of $967,497.
How old is Bo Kruse?
Bo Kruse is 48, he's been the Chief Financial Officer, Executive Vice President, Treasurer, Secretary и Director of Y-Mabs Therapeutics Inc since 2015. There are 14 older and 5 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
What's Bo Kruse's mailing address?
Bo's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Insiders trading at Y-Mabs Therapeutics Inc
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad и Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
What does Y-Mabs Therapeutics Inc do?
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
What does Y-Mabs Therapeutics Inc's logo look like?
Complete history of Mr. Kruse stock trades at Y-Mabs Therapeutics Inc
Y-Mabs Therapeutics Inc executives and stock owners
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
CEO & Director -
Claus Moller-San Pedro,
Chief Executive Officer, Director -
Thomas Gad,
Chairman of the Board, President, Founder, Head of Business Development and Strategy -
Thomas Gad,
Founder, Chairman, Pres and Head of Bus. Devel. & Strategy -
Bo Kruse,
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director -
Bo Kruse,
Exec. VP, Sec., Treasurer & CFO -
David Gill,
Independent Director -
James Healy,
Independent Director -
Ashutosh Tyagi,
Independent Director -
Gerard Ber,
Independent Director -
Johan Wedell-Wedellsborg,
Independent Director -
Torben Lund-Hansen,
Senior Vice President, Chief Technical Officer -
Steen Lisby,
Senior Vice President, Chief Medical Officer -
Philip Herman,
Senior Vice President and Chief Commercial Officer -
Mahiuddin Ahmed,
Senior Vice President, Chief Scientific Officer -
Joris Wilms,
Chief Operating Officer, Senior Vice President -
Sue Smith,
Sr. VP & Chief Commercial Officer -
Dr. Torben Lund-Hansen,
Sr. VP & Chief Technical Officer -
Joris Wiel Jan Wilms,
Sr. VP & COO -
Dr. Vignesh Rajah,
Sr. VP & Chief Medical Officer -
Dr. Steen Lisby M.D., M.Sc.,
Sr. VP & Chief Scientific Officer -
Peter P. Pfreundschuh,
CFO and Treasurer -
Gregory S Raskin,
Director -
Ashu Tyagi,
Director -
Mary Tagliaferri,
Director -
Laura Hamill,
Director -
Vignesh Rajah,
SVP & CHIEF MEDICAL OFFICER -
Biotech Ap S Wg,
Director -
Susan Laura Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Michael J Rossi,
PRESIDENT & CEO